In part two of her DPHARM interview, Andrea Valente, CEO of uMotif, explains why the real technology challenge isn't ...

In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across ...

Benchmarking data showed sourcing approach did not reliably predict timeline, quality, or execution performance across 133 ...

In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more ...

A platform-based approach connects AI across workflows, data and governance, helping life sciences organizations move from isolated wins to real scale.

In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system ...

In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, discussed the patient-site relationship, the role of technology in clinical trial delivery ...

A platform-based approach connects AI across workflows, data and governance, helping life sciences organizations move from isolated wins to real scale. AI adoption is moving quickly in life sciences, ...

Why clinical development’s next AI bottleneck is not the model, but the system around it.

The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol ...

Comparable expectations are emerging in the EU and UK through separate instruments. For organizations that already hold ...